{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:55:31Z","timestamp":1793328931254,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Radiation Oncology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.semradonc.2025.05.004","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T19:15:56Z","timestamp":1749755756000},"page":"317-324","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["PSMA-PET Guided Radiotherapy in Prostate Cancer: A Critical Review of Current Applications and Future Directions"],"prefix":"10.1016","volume":"35","author":[{"given":"Valentino","family":"Dragonetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Colandrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Travaini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lighea Simona","family":"Air\u00f2 Farulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ceci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9523-7315","authenticated-orcid":false,"given":"Francesco","family":"Mattana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.semradonc.2025.05.004_bib0001","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer\u20142024 Update. Part I: screening, diagnosis, and local treatment with curative Intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"issue":"10231","key":"10.1016\/j.semradonc.2025.05.004_bib0002","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"The Lancet"},{"issue":"5","key":"10.1016\/j.semradonc.2025.05.004_bib0003","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2967\/jnumed.120.246603","article-title":"Identification of PCWG3 target populations is more accurate and reproducible with PSMA PET than with conventional imaging: a multicenter retrospective study","volume":"62","author":"Farolfi","year":"2021","journal-title":"J Nucl Med"},{"issue":"24","key":"10.1016\/j.semradonc.2025.05.004_bib0004","doi-asserted-by":"crossref","first-page":"7448","DOI":"10.1158\/1078-0432.CCR-19-1050","article-title":"Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer","volume":"25","author":"Fendler","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.semradonc.2025.05.004_bib0005","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.eururo.2023.10.012","article-title":"The efficacy and safety of metastasis-directed therapy in patients with prostate cancer: a systematic review and meta-analysis of prospective Studies","volume":"85","author":"Miszczyk","year":"2024","journal-title":"Eur Urol"},{"issue":"5B","key":"10.1016\/j.semradonc.2025.05.004_bib0006","first-page":"927","article-title":"Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients","volume":"7","author":"Horoszewicz","year":"1987","journal-title":"Anticancer Res"},{"issue":"7","key":"10.1016\/j.semradonc.2025.05.004_bib0007","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.2967\/jnumed.117.203877","article-title":"A Perspective on the Evolving Story of PSMA Biology, PSMA-Based Imaging, and Endoradiotherapeutic Strategies","volume":"59","author":"O\u2019Keefe","year":"2018","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/j.semradonc.2025.05.004_bib0008","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II\u20142024 Update: Treatment of Relapsing and Metastatic Prostate Cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.05.004_bib0009","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2023.09.003","article-title":"European Association of Nuclear Medicine Focus 5: Consensus on molecular imaging and theranostics in prostate cancer","volume":"85","author":"DE","year":"2024","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.05.004_bib0010","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41391-023-00755-2","article-title":"Comparison of 18F-based PSMA radiotracers with [68Ga]Ga-PSMA-11 in PET\/CT imaging of prostate cancer\u2014a systematic review and meta-analysis","volume":"27","author":"Huang","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"12","key":"10.1016\/j.semradonc.2025.05.004_bib0011","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1007\/s00259-024-06797-5","article-title":"The Homunculus of unspecific bone uptakes associated with PSMA-targeted tracers: a systematic review-based definition","volume":"51","author":"Rizzo","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"10.1016\/j.semradonc.2025.05.004_bib0012","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.3390\/cancers14092073","article-title":"Local control after locally ablative, image-guided radiotherapy of oligometastases identified by Gallium-68-PSMA-positron emission tomography in castration-sensitive prostate cancer patients (OLI-P)","volume":"14","author":"H\u00f6lscher","year":"2022","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.semradonc.2025.05.004_bib0013","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.semradonc.2025.05.004_bib0014","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II\u20142024 Update: Treatment of Relapsing and Metastatic Prostate Cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.05.004_bib0015","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.euo.2023.01.014","article-title":"Metastatic Sites\u2019 Location and Impact on Patient Management After the Introduction of Prostate-specific Membrane Antigen Positron Emission Tomography in Newly Diagnosed and Biochemically Recurrent Prostate Cancer: A Critical Review","volume":"6","author":"Mattana","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.05.004_bib0016","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13014-018-1036-8","article-title":"Focal dose escalation for prostate cancer using 68Ga-HBED-CC PSMA PET\/CT and MRI: a planning study based on histology reference","volume":"13","author":"Zamboglou","year":"2018","journal-title":"Radiat Oncol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.05.004_bib0017","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.ijrobp.2022.04.020","article-title":"PSMA-PET- and MRI-based focal dose escalated radiation therapy of primary prostate cancer: planned safety analysis of a nonrandomized 2-armed Phase 2 Trial (ARO2020-01)","volume":"113","author":"Zamboglou","year":"2022","journal-title":"Int J Radiat Oncol"},{"issue":"3","key":"10.1016\/j.semradonc.2025.05.004_bib0018","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1016\/j.prro.2021.09.008","article-title":"Early Outcomes and Decision Regret Using PSMA\/MRI-Guided Focal Boost for Prostate Cancer SBRT","volume":"12","author":"Eade","year":"2022","journal-title":"Pract Radiat Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.05.004_bib0019","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00259-018-4189-7","article-title":"68Ga-PSMA-11 PET\/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy","volume":"46","author":"Ceci","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.semradonc.2025.05.004_bib0020","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41391-022-00544-3","article-title":"The impact of PSMA PET on the treatment and outcomes of men with biochemical recurrence of prostate cancer: a systematic review and meta-analysis","volume":"26","author":"Pozdnyakov","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"10288","key":"10.1016\/j.semradonc.2025.05.004_bib0021","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(21)00581-X","article-title":"18F-fluciclovine-PET\/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2\/3 randomised controlled trial","volume":"397","author":"Jani","year":"2021","journal-title":"The Lancet"},{"issue":"22","key":"10.1016\/j.semradonc.2025.05.004_bib0022","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.3390\/cancers13225795","article-title":"PSMA-PET\/MRI-based focal dose escalation in patients with primary prostate cancer treated with stereotactic body radiation therapy (HypoFocal-SBRT): study protocol of a randomized, multicentric phase III trial","volume":"13","author":"Zamboglou","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.semradonc.2025.05.004_bib0023","doi-asserted-by":"crossref","DOI":"10.2196\/60323","article-title":"A machine learning approach for predicting biochemical outcome after PSMA-PET\u2013guided salvage radiotherapy in recurrent prostate cancer after radical prostatectomy: retrospective study","volume":"10","author":"Janbain","year":"2024","journal-title":"JMIR Cancer"},{"issue":"5","key":"10.1016\/j.semradonc.2025.05.004_bib0024","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.14748","article-title":"Development and validation of a multi-institutional nomogram of outcomes for PSMA-PET-based salvage radiotherapy for recurrent prostate cancer","volume":"6","author":"Zamboglou","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.semradonc.2025.05.004_bib0025","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.05.004_bib0026","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"issue":"29","key":"10.1016\/j.semradonc.2025.05.004_bib0027","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1200\/JCO.22.00644","article-title":"Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials","volume":"40","author":"Deek","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.semradonc.2025.05.004_bib0028","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S1470-2045(24)00730-7","article-title":"ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial","volume":"26","author":"Marvaso","year":"2025","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.semradonc.2025.05.004_bib0029","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.semradonc.2025.05.004_bib0030","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.semradonc.2025.05.004_bib0031","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.05.004_bib0032","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.eururo.2024.09.020","article-title":"A Meta-Analysis and Meta-Regression of the Efficacy, Toxicity, and Quality of Life Outcomes Following Prostate-Specific Membrane Antigen Radioligand Therapy Utilising Lutetium-177 and Actinium-225 in Metastatic Prostate Cancer","volume":"87","author":"Dai","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2025.05.004_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.prro.2025.03.010","article-title":"Combination metastasis-targeted external beam radiation therapy with 177Lu-PSMA-617 in patients with advanced castration-resistant prostate cancer","author":"Mohammadi","year":"2025","journal-title":"Pract Radiat Oncol"},{"issue":"6","key":"10.1016\/j.semradonc.2025.05.004_bib0034","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.7150\/thno.93249","article-title":"Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [177Lu]Lu-PSMA-617 for prostate cancer - from bench to bedside","volume":"14","author":"Arbuznikova","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.semradonc.2025.05.004_bib0035","series-title":"Tolerability of Concurrent EBRT + Lu-PSMA for Node-Positive Prostate Cancer (PROQURE-1)","year":"2024"},{"key":"10.1016\/j.semradonc.2025.05.004_bib0036","unstructured":"Novartis. An open-label study comparing lutetium (177Lu) vipivotide tetraxetan versus observation in PSMA positive OMPC. Accessed April 23, 2025. https:\/\/www.novartis.com\/clinicaltrials\/study\/nct05939414"},{"issue":"5","key":"10.1016\/j.semradonc.2025.05.004_bib0037","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","article-title":"PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0","volume":"50","author":"Fendler","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1016\/j.semradonc.2025.05.004_bib0038","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","article-title":"E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET","volume":"48","author":"Ceci","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1016\/j.semradonc.2025.05.004_bib0039","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.eururo.2023.06.008","article-title":"Prostate-specific Membrane Antigen Reporting and Data System Version 2.0","volume":"84","author":"Werner","year":"2023","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.05.004_bib0040","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)","volume":"83","author":"Seifert","year":"2023","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.05.004_bib0041","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.eururo.2025.01.003","article-title":"The Co-IMPACT consortium: integrating prostate-specific membrane antigen positron emission tomography and radiotherapy in prostate cancer care","volume":"87","author":"Murthy","year":"2025","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.05.004_bib0042","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2024.09.017","article-title":"Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)","volume":"87","author":"Gillessen","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2025.05.004_bib0043","unstructured":"RadioGraphics. Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls. Accessed April 23, 2025.https:\/\/pubs.rsna.org\/doi\/10.1148\/rg.2018170108?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed"},{"issue":"12","key":"10.1016\/j.semradonc.2025.05.004_bib0044","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.2967\/jnumed.122.264321","article-title":"Joint EANM, SNMMI, and IAEA enabling guide: how to set up a theranostics center","volume":"63","author":"Herrmann","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.semradonc.2025.05.004_bib0045","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.124.268818","article-title":"The role of PSMA PET parameters as biomarkers for response to PSMA-targeted radiopharmaceutical therapy","author":"Murthy","year":"2025","journal-title":"J Nucl Med"}],"container-title":["Seminars in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429625000475?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429625000475?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T15:06:18Z","timestamp":1750777578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053429625000475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1053429625000475"],"URL":"https:\/\/doi.org\/10.1016\/j.semradonc.2025.05.004","relation":{},"ISSN":["1053-4296"],"issn-type":[{"value":"1053-4296","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PSMA-PET Guided Radiotherapy in Prostate Cancer: A Critical Review of Current Applications and Future Directions","name":"articletitle","label":"Article Title"},{"value":"Seminars in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semradonc.2025.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}